Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2005.07.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on tyrosine kinase inhibitor therapy.
Leuk Lymphoma
January 2025
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Unusual Co-Occurrence of Multiple Myeloma and AML in a Patient With Germline CEBPA Variant. Expanding the Spectrum of Hereditary Hematologic Malignancies.
Clin Genet
January 2025
Laboratorio de Citometría y Biología Molecular, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay.
Timeline and genetic analysis of a 55-year-old female with a family history of gastric cancer and multiple myeloma, who was diagnosed with AML and a germline CEBPA variant.
View Article and Find Full Text PDFKaleidoscopic Chloroma: An Unusual Case of Myeloid Sarcoma.
Cureus
December 2024
Radiology, Tata Main Hospital, Jamshedpur, IND.
We report a 37-year-old male patient who had nonbilious vomiting, no passage of flatus, and recurring abdominal pain. This patient had de novo intestinal myeloid sarcoma (MS), a rare and chameleonic presentation of acute leukemia of myeloid origin. The initial diagnostic evaluation suggested Koch's abdomen, and surgical excision of the bowel was performed with a clinical suspicion of Koch's or lymphoma.
View Article and Find Full Text PDFA germline FLT3 variant in aplastic anemia.
Biomark Res
January 2025
Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA.
FMS-like tyrosine kinase 3 (FLT3) genetic variants are commonly seen in high-grade myeloid neoplasms and are typically gain-of-function mutations associated with a proliferative disease phenotype. Inactivating FLT3 variants have been less frequently described in non-malignant, autoimmune disorders and are uncommon in aplastic anemia (AA). Herein, we report the first to our knowledge, and unusual case of a germline, gain-of-function, FLT3 variant in a patient with severe AA treated successfully with immunosuppressive therapy.
View Article and Find Full Text PDFRisk Factors for Venous Thromboembolism in Acute Promyelocytic Leukemia.
Cancers (Basel)
December 2024
Clinic of Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Background: Acute promyelocytic leukemia (APL) is frequently associated with disseminated intravascular coagulation (DIC), leading to potentially life-threatening bleeding. Compared to bleeding, thromboses are a less commonly encountered problem.
Objective: The objective of our study was to identify the incidence and predictive value of demographic data, clinical-laboratory parameters, and thrombosis risk assessment models (RAMs) for venous thromboembolism (VTE) in patients with APL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!